1449782-38-0

Basic information

• Product Name: N-(6-morpholino-9-[2-(1H-tetrazol-5-yl)ethyl]-9H-purin-2-yl)cyclohexanecarboxamide
• Synonyms: N-(6-morpholino-9-[2-(1H-tetrazol-5-yl)ethyl]-9H-purin-2-yl)cyclohexanecarboxamide
• CAS NO: 1449782-38-0
• Molecular Weight: 426.481
• Mol File: 1449782-38-0.mol

Chemical Properties

• CAS DataBase Reference: N-(6-morpholino-9-[2-(1H-tetrazol-5-yl)ethyl]-9H-purin-2-yl)cyclohexanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-morpholino-9-[2-(1H-tetrazol-5-yl)ethyl]-9H-purin-2-yl)cyclohexanecarboxamide(1449782-38-0)
• EPA Substance Registry System: N-(6-morpholino-9-[2-(1H-tetrazol-5-yl)ethyl]-9H-purin-2-yl)cyclohexanecarboxamide(1449782-38-0)

Safety Data

• Hazardous Substances Data: 1449782-38-0(Hazardous Substances Data)

Upstream product

• 1449782-36-8 6-morpholino-9-[2-(1H-tetrazol-5-yl)ethyl]-9H-purine-2-amine 
• 2719-27-9 cyclohexanylcarbonyl chloride 

Relevant articles and documents

A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells

A focused library of hetero-trisubstituted purines was developed for improving the cell penetrating and biological efficacy of a series of anti-Stat3 protein inhibitors. From this SAR study, lead agent 22e was identified as being a promising inhibitor of MM tumour cells (IC50's 5 μM). Surprisingly, biophysical and biochemical characterization proved that 22e was not a Stat3 inhibitor. Initial screening against the kinome, prompted by the purine scaffold's history for targeting ATP binding pockets, suggests possible targeting of the JAK family kinases, as well for ABL1 (nonphosphorylated F317L) and AAK1.